In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine (Q35993981)

11 August 2017

In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine (English)

1 reference

11 August 2017

1 reference

Peters GJ

1

1 reference

11 August 2017

Kraal I

series ordinal

2

1 reference

11 August 2017

Pinedo HM

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 1992

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

65

1 reference

11 August 2017

2

1 reference

11 August 2017

229-233

1 reference

Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Biochemical modulation: application of laboratory models to the clinic

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

On the Role of Dihydroorotate Dehydrogenase in Growth Cessation of Ehrlich Ascites Tumor Cells Cultured under Oxygen Deficiency

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977736

Cellular pharmacology of DUP-785, a new anticancer agent

11 July 2018

1 reference

12 December 2020

Distribution of the novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts

1 reference

12 December 2020

DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects

1 reference

12 December 2020

Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)

1 reference

12 December 2020

Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis

1 reference

12 December 2020

Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites

1 reference

12 December 2020

Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake

1 reference

12 December 2020

In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients

1 reference

12 December 2020

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies

1 reference

12 December 2020

Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1992.46

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

1739622

1 reference